血管激素受体抑制剂在痴呆症预防中的使用
Jordana de Araujo Müller1, Laura Jacques Giacobe1, Vanise Grassi1
1Universidade do Vale do Taquari, Centro de Ciências Médicas, Lajeado RS, Brazil.
Dementia & neuropsychologia
|September 8, 2023
概括
血管激素受体阻断剂 (ARBs) 显示出预防痴呆的潜力. 这一系统性审查表明ARB可能比其他抗高血压药在抗阿尔茨海默病的神经保护方面更有效.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 阿尔茨海默病 (AD) 和痴呆症是普遍存在的,可能是可以预防的疾病.
- 系统性动脉高血压也非常普遍.
- 抗高血压治疗和神经保护之间存在潜在的联系,特别是关于ARBs.
研究的目的:
- 系统地审查和评估抗阿尔茨海默病 (AD) 的血管激素受体抑制剂 (ARB) 的神经保护作用.
- 评估ARB使用是否在被诊断为轻度认知障碍的人群中具有保护性益处.
主要方法:
- 来自Embase,LILACS,SciELO和PubMed的研究的系统审查.
- 纳入标准:评估轻度认知障碍患者使用抗高血压药物的研究.
- 使用Cochrane EPOC表格提取数据,并使用EPOC"偏差风险工具"评估偏差风险.
主要成果:
- 确定了12个物品,其中3个被选中进行详细分析.
- 两篇精选的文章比较了ARB/ACEI与其他抗高血压剂的使用,以了解痴呆症的发展.
- 一个趋势表明ARBs在痴呆症预防中可能优于其他抗高血压药物.
结论:
- 与其他抗高血压药物相比,ARB在预防痴呆症方面具有潜在的优势.
- 需要进一步的研究来证实ARBs在阿尔茨海默病和相关痴呆症中的神经保护作用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
Antihypertensive Drugs: Angiotensin II Receptor Blockers
776
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
776
Antihypertensive Drugs: Direct Renin Inhibitors
677
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
677
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
687
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
687
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139


